THE WOODLANDS, Texas, Feb. 02, 2017 -- Smart Sand, Inc. (the “Company”) has priced a public offering of 5,950,000 shares of its common stock at $17.50 per share, of which 1,500,000 shares are to be sold by the Company and 4,450,000 shares are to be sold by the selling stockholders named in the registration statement on Form S-1 filed previously with the U.S. Securities and Exchange Commission (“SEC”). The selling stockholders have granted the underwriters a 30-day option to purchase from the selling stockholders up to an additional 892,500 shares of the Company’s common stock. The Company’s shares of common stock are traded on the NASDAQ Global Select Market under the ticker symbol “SND.” The offering is expected to close on February 7, 2017, subject to customary closing conditions.
The Company intends to use the net proceeds it receives from the offering for future capital projects and general corporate purposes. The Company will not receive any net proceeds from the sale by the selling stockholders of shares of the Company’s common stock.
Credit Suisse, Goldman, Sachs & Co. and Jefferies are acting as book-running managers for the public offering. Additional book-running managers are Piper Jaffray & Co., Tudor, Pickering, Holt & Co. and Deutsche Bank Securities.
The public offering is being made only by means of a written prospectus that meets the requirements of Section 10 of the Securities Act of 1933, copies of which may be obtained from:
| Credit Suisse Attention: Prospectus Department One Madison Avenue New York, NY 10010 Telephone: (800) 221-1037 Email: [email protected] | Goldman, Sachs & Co. Attention: Prospectus Department 200 West Street New York, NY 10282 Telephone: (212) 902-1171 Email: [email protected] |
A registration statement relating to these securities has been filed and declared effective by the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
When available, to obtain a copy of the prospectus free of charge, visit the SEC’s website, www.sec.gov, and search under the registrant’s name, “Smart Sand, Inc.”
About Smart Sand:
Smart Sand, Inc. is a pure-play, low-cost producer of high-quality Northern White raw frac sand, which is a preferred proppant used to enhance hydrocarbon recovery rates in the hydraulic fracturing of oil and natural gas wells. Northern White raw frac sand, which is found predominantly in Wisconsin and limited portions of Minnesota and Illinois, is highly valued by oil and natural gas producers as a preferred proppant due to its favorable physical characteristics.
Contact: Lee Beckelman Phone: (281) 231-2658 E-mail: [email protected] Phil Cerniglia Phone: (281) 231-2660 E-mail: [email protected]


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FDA Approves Mitapivat for Anemia in Thalassemia Patients
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



